Pancreatic Cancer Research

ResearcherUniversity of Wisconsin–MadisonActive in the last 2 years

Sharon Marie Weber

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8668-3687; OpenAlex author ID A5103079074, A5122560062. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
58
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 21

  1. Novel Electronic Health Record-Based Data Commons for Pancreatic Cancer. Co-author DOI 10.1200/cci-24-00265↗
  2. Assessing the Evidence for Neoadjuvant Chemotherapy in Patients with Resectable Pancreatic Adenocarcinoma Using the Robustness of Inference to Replacement. Co-author DOI 10.1245/s10434-026-19443-1↗
  3. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  4. Neoadjuvant Stereotactic Body Radiation Therapy Plus Elective Nodal Irradiation With Concurrent Capecitabine for Patients With Resectable Pancreatic Cancer: Su… Co-author DOI 10.1016/j.prro.2025.01.011↗
  5. Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-023-14347-w↗
  6. Treatment Inequity: Examining the Influence of Non-Hispanic Black Race and Ethnicity on Pancreatic Cancer Care and Survival in Wisconsin. Co-author PMID 35857681↗
  7. A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2020.09.010↗
  8. A narrative review: has regionalization truly achieved its intended goal in the surgical management of pancreatic cancer? First author DOI 10.21037/cco-21-54↗
  9. National Trends in Centralization of Surgical Care and Multimodality Therapy for Pancreatic Adenocarcinoma. Last author DOI 10.1007/s11605-019-04361-3↗
  10. Natural History and Treatment Trends in Pancreatic Cancer Subtypes. Co-author DOI 10.1007/s11605-019-04113-3↗
  11. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  12. Editorial About: "A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation fo… Last author DOI 10.1245/s10434-019-07737-6↗
  13. Cohort Study of Overutilization of Preventive Screening for Patients With Pancreatic Cancer Co-author DOI 10.1097/mpa.0000000000001131↗
  14. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer. Last author DOI 10.1245/s10434-018-6650-z↗
  15. Human pancreatic stellate cells modulate 3D collagen alignment to promote the migration of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1007/s10544-016-0128-1↗
  16. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. Co-author DOI 10.18632/oncotarget.12772↗
  17. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-ins… Co-author DOI 10.1007/s11605-014-2567-4↗
  18. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  19. A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. Co-author DOI 10.1039/c3lc50487e↗
  20. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. Co-author DOI 10.1111/j.1477-2574.2011.00432.x↗
  21. Medically managed hypercholesterolemia and insulin-dependent diabetes mellitus preoperatively predicts poor survival after surgery for pancreatic cancer. Co-author DOI 10.1007/s11605-011-1448-3↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel Erik Abbott · 11 shared papers, 2014–2025 · strength 1.20
  2. Syed Nabeel Zafar · 5 shared papers, 2022–2026 · strength 1.11
  3. Noelle K. LoConte · 5 shared papers, 2021–2026 · strength 0.88
  4. Sean M. Ronnekleiv‐Kelly · 5 shared papers, 2018–2025 · strength 0.62
  5. Benjamin A. Y. Cher · 2 shared papers, 2025–2026 · strength 0.53
  6. Nataliya Volodymyrivna Uboha · 3 shared papers, 2019–2025 · strength 0.47
  7. kaleem sohail Ahmed · 2 shared papers, 2024–2026 · strength 0.43
  8. Clayton Thomas Marcinak · 2 shared papers, 2024–2026 · strength 0.43
  9. Andrea M. Schiefelbein · 2 shared papers, 2022–2026 · strength 0.40
  10. Alexander V. Fisher · 4 shared papers, 2018–2020 · strength 0.39
  11. Emily R. Winslow · 7 shared papers, 2011–2019 · strength 0.37
  12. Syed Ameen Ahmad · 6 shared papers, 2011–2025 · strength 0.37
  13. Charles Raben Scoggins · 6 shared papers, 2011–2025 · strength 0.37
  14. Robert C.G. Martin · 6 shared papers, 2011–2025 · strength 0.37
  15. Nipun B. Merchant · 5 shared papers, 2012–2025 · strength 0.35
  16. Shishir Kumar Maithel · 4 shared papers, 2014–2025 · strength 0.33
  17. Michael Frederick Bassetti · 2 shared papers, 2021–2025 · strength 0.31
  18. Jacob S. Witt · 2 shared papers, 2021–2025 · strength 0.31
  19. Alexander A. Parikh · 4 shared papers, 2012–2025 · strength 0.28
  20. Sameer H. Patel · 2 shared papers, 2019–2025 · strength 0.27
  21. Muhammad Maisam Ali · 1 shared paper, 2026 · strength 0.26
  22. Patrick Beard Schwartz · 2 shared papers, 2019 · strength 0.23
  23. Alexandra W. Acher · 1 shared paper, 2021 · strength 0.22
  24. Timothy Michael Pawlik · 1 shared paper, 2021 · strength 0.22
  25. Jeremy D. Kratz · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.